IMRN News and Press, Immuron Limited From 12/04/23

Highlights: First participants enrolled in the US Naval Medical Research Command Clinical Trial Clinical Study initiated to evaluate the efficacy of a new Immuron clinical product to protecting volunteers against moderate to severe campylobacteriosis New CampETEC pro...

MELBOURNE, Australia, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to invite shareholders to attend an investor webinar “Coffee Microcaps Morning Meeting”, to be held on T...

MELBOURNE, Australia, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to invite shareholders to attend an investor webinar on The Watchlist, to be held on Tuesday, 14th November, 2023, 1:0...

MELBOURNE, Australia, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company, is pleased to advise our Chief Executive Officer, Steven Lydeamore, presented at AusBioInvest 2023 on Monday, October 30th in th...

Highlights: Second cohort of 34 healthy volunteers enrolled in the Travelan ® Clinical Trial Clinical Trial to examine a dosing regimen for Travelan ® more suited to the US military has commenced the second cohort The clinical study 6 month follow u...

2023-10-11 06:19:30 ET More on Immuron Financial information for Immuron For further details see: Immuron achieves record quarterly travelan® sales

Highlights: Record quarterly Travelan ® sales of $1,550,240 Total sales of A$1,565,767 in Q1, FY24 $1,508,933 increase on Q1, FY23 sales 130% higher than pre-pandemic period Q1, FY20 sales MELBOURNE, Australia, Oct. 11, 2023 (GLOBE NEWSWI...

Presentation on Wednesday, October 4th at 11:00 PT Melbourne, Australia--(Newsfile Corp. - September 18, 2023) - Immuron Limited (NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company, announced today that it will be presenting at the 16th annual Main Event on We...

Highlights: Record monthly Travelan ® sales Australian sales of A$1.18 M in August 2023 (7984% increase on August 2022 sales) MELBOURNE, Australia, Sept. 13, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally ...

MELBOURNE, Australia, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to advise our Chief Executive Officer, Steven Lydeamore will be presenting virtually at the H.C. Wainwright 25 th ...